

Trust Board

11th November 2021

Paper title:	NHS England & NHS Improvement Quarterly Return Declaration	Agenda item 25
Presented by:	Mike Woodhead, Director of Finance, Contracting & Estates	
Prepared by:	Claire Risdon, Deputy Director of Finance	

Purpose of the report		
The purpose of this report is to share the recommendation from the Finance Business and Investment Committee that the Trust Board formally approve the Quarter 2 NHS England & NHS Improvement financial submission.	For approval	X
	For discussion	
	For information	

Executive summary		
<p>The purpose of this report is to share the recommendation from the Finance Business and Investment Committee that the Trust Board formally approve the Quarter 2 NHS England & NHS Improvement (NHSEI) financial submission. Key points in considering this report are that the Trust has delivered the following financial indicators for quarter 2 of 2021/22:</p> <ul style="list-style-type: none"> Revenue: YTD position of £19k surplus (£19k better than plan). Closing cash balance at the end of September of £30.885m. Cash is forecast to be £30.063m at the 31st March 2022. Capital YTD expenditure is £2.342m against a plan of £3.07m (note that the revised capital plan was not approved). The full year forecast is £5.78m which is £250k less than plan. Use of Resources - reporting is currently suspended due to COVID-19 		
Do the recommendations in this paper have any impact upon the requirements of the protected groups identified by the Equality Act?	State below 'Yes' or 'No'	If yes please set out what action has been taken to address this in your paper
	No	

Strategic vision				
Providing excellent quality services and seamless access	Creating the best place to work	Supporting people to live to their fullest potential	Financial sustainability growth and innovation	Governance and well-led
			X	X
Recommendation				
The Trust Board is asked to: <ul style="list-style-type: none"> Retrospectively approve the Q2 quarterly submission made to NHS England & NHS Improvement 				

Care Quality Commission domains				
Please mark those that apply with an X				
Safe	Effective	Responsive	Caring	Well Led
	X			X

Relationship to the Board Assurance Framework (BAF)	The work contained with this report links to the following strategic risk(s) as identified in the BAF: <ul style="list-style-type: none"> SO6: To make effective use of our resources to ensure that services are clinically, environmentally, and financially sustainable
Links to the Corporate Risk Register (CRR)	The work contained with this report links to the following corporate risk(s) as identified in the CRR: <ul style="list-style-type: none"> 2536 If we do not make effective use of our resources this may result in regulatory interventions, as well as impacts on quality of services.
Compliance and regulatory implications	The following compliance and regulatory implications have been identified as a result of the work outlined in this report: <ul style="list-style-type: none"> NHS Foundation Trusts were required to make quarterly submissions to NHSEI to confirm their Risk Rating under the Single Oversight Framework (SOF). From August 2019 the NHS Oversight Framework replaced the provider SOF and the clinical commissioning group (CCG) Improvement and Assessment Framework (IAF) and will inform assessment of providers in 2021/22 and beyond. For providers, the Risk Assessment Rating reflects a single consolidated rating which is 'Use of Resources' (UoR). This paper considers the UoR and outlines key issues which the FBIC is specifically asked to consider in endorsing the risk assessment and to be taken into account when the Board considers the NHSEI submission. Adverse performance compared to plan and/or a high risk rating generates closer support/scrutiny.

Meeting of the Trust Board

11th November 2021

NHS England & NHS Improvement Quarterly Return and Declaration

1. Background and Context

NHS Foundation Trusts are required to make quarterly submissions to NHS England & NHS Improvement to confirm their Risk Rating under the Single Oversight Framework (SOF). From August 2019 the NHS Oversight Framework replaced the provider SOF and the clinical commissioning group (CCG) Improvement and Assessment Framework (IAF) and will inform assessment of providers in 2021/22. For providers, the Risk Assessment Rating reflects a single consolidated rating which is 'Use of Resources' (UoR).

The Systems Oversight Framework is being developed and is expected to be operational for 2022/23.

This paper considers the UoR and outlines key issues which the FBIC is specifically asked to consider in endorsing the risk assessment and to be taken into account when the Board considers the NHS England & NHS Improvement submission.

The Trust is not currently reporting an UoR rating as reporting is suspended due to COVID-19.

2. Considerations

The key points are that the Trust has delivered the following financial indicators for quarter 2 of 2021/22:

- Trust performance for the period April 2021 to September 2021 is a surplus of £19k compared to a planned breakeven position resulting in a favourable variance of £19k.
- Capital YTD expenditure is £2.342m against a plan of £3.07m (note that the revised capital plan was not approved). The full year forecast is £5.78m which is £250k below plan.
- Cash – Closing cash balance at the end of September of £30.885m. Cash is forecast to be £30.063m at the 31st March 2022.
- UoR – reporting is currently suspended due to COVID-19

The M06 financial templates were submitted to NHSEI on the 15th October 2021.

3. Implications

3.1 Legal and Constitutional

There are no legal or constitutional requirements in relation to this paper.

3.2 Resource

There are no direct financial implications / costs associated with this paper.

3.3 Quality and Compliance

Financial performance is a key measure under the NHS England & NHS Improvement Single Oversight Framework. Any cost improvements planned by the Trust are subject to a Quality Impact Assessment process overseen by the Medical Director and the Chief Operating Officer.

4. Communication and Involvement

The Board was sighted on key plan risks and additional scrutiny of key assumptions, risks and mitigation takes place at every Finance, Business and Investment Committee. Key messages are discussed through the Trust's Senior Leadership Team and through the Trust's current command structures.

5. Monitoring and review

The Finance, Business and Investment Committee review and formally recommend the NHS England & NHS Improvement Quarterly submission to Trust Board following each quarter end.

Name of author	Claire Risdon
Title	Deputy Director of Finance
Date paper written	15 th October 2021